- Home
- ARMP vs YI Comparison
ARMP vs YI Comparison
Compare ARMP & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- YI
- Stock Information
- Founded
- ARMP N/A
- YI 2010
- Country
- ARMP United States
- YI China
- Employees
- ARMP N/A
- YI N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- ARMP Health Care
- YI Consumer Staples
- Exchange
- ARMP Nasdaq
- YI Nasdaq
- Market Cap
- ARMP 80.0M
- YI 64.4M
- IPO Year
- ARMP N/A
- YI N/A
- Fundamental
- Price
- ARMP $2.72
- YI $0.67
- Analyst Decision
- ARMP Strong Buy
- YI
- Analyst Count
- ARMP 1
- YI 0
- Target Price
- ARMP $7.00
- YI N/A
- AVG Volume (30 Days)
- ARMP 8.3K
- YI 108.0K
- Earning Date
- ARMP 11-13-2024
- YI 11-27-2024
- Dividend Yield
- ARMP N/A
- YI N/A
- EPS Growth
- ARMP N/A
- YI N/A
- EPS
- ARMP N/A
- YI N/A
- Revenue
- ARMP $3,719,000.00
- YI $2,026,540,888.00
- Revenue This Year
- ARMP N/A
- YI $61.85
- Revenue Next Year
- ARMP $83.33
- YI N/A
- P/E Ratio
- ARMP N/A
- YI N/A
- Revenue Growth
- ARMP N/A
- YI 0.38
- 52 Week Low
- ARMP $1.93
- YI $0.55
- 52 Week High
- ARMP $4.48
- YI $2.38
- Technical
- Relative Strength Index (RSI)
- ARMP 67.03
- YI 40.74
- Support Level
- ARMP $2.21
- YI $0.65
- Resistance Level
- ARMP $2.96
- YI $0.70
- Average True Range (ATR)
- ARMP 0.15
- YI 0.04
- MACD
- ARMP 0.05
- YI -0.01
- Stochastic Oscillator
- ARMP 68.42
- YI 12.60
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.